1. Somatic mutations involving TSC 1 and TSC2 genes in two children with focal cortical dysplasia
- Author
-
Uday Bhanu Kovilapu, Rakesh Ranjan, Vishal Sondhi, Ruchika Jha, and Arjun Kurup
- Subjects
Pathology ,medicine.medical_specialty ,Somatic cell ,business.industry ,General Medicine ,Cortical dysplasia ,medicine.disease ,Frameshift mutation ,Epilepsy ,medicine.anatomical_structure ,Developmental Neuroscience ,Pediatrics, Perinatology and Child Health ,medicine ,Missense mutation ,Neurology (clinical) ,TSC1 ,TSC2 ,business ,PI3K/AKT/mTOR pathway - Abstract
Background The role of PI3K/AKT/mTOR pathway hyperactivation in localized brain overgrowth is evolving. We describe two patients with focal cortical dysplasia (FCD) who demonstrated somatic mutations in TSC1 and TSC2 genes in the dysplastic brain tissue but not peripheral blood. Methods Paired whole-exome sequencing was performed on genomic DNA extracted from blood and excised brain tissue in two children with FCD who underwent excision of dysplastic tissue. Results Patient 1, a 14-year boy, had drug-resistant focal epilepsy with onset at 20 months. His brain MRI showed abnormalities suggestive of FCD in the left superior and middle frontal lobes. Patient 2 presented at the age of 10 years with pharmaco-resistant focal epilepsy (onset at six years). His MRI suggested FCD in the left insular lobe. Both patients underwent surgical excision of FCD, and excised tissues were pathologically confirmed to have type IIb FCD. For patient 1, a missense mutation (c.64C > T; p.Arg22Trp) was detected in the TSC1 gene in DNA of dysplastic brain tissue but not peripheral blood lymphocytes. Similarly, for patient 2, a frameshift mutation (c.4258_4261delCAGT; p.Ser1420GlyfsTer55) in the TSC2 gene was identified in the brain tissue but not blood. Both gene variants are likely pathogenic and cause mTOR pathway activation. Conclusion Our report of TSC1/TSC2 somatic mutations in patients with non-syndromic FCD suggests that localized hyperactivation of the mTOR pathway can cause focal malformations during cortical development and presents pharmacological targets for precision therapy in FCD management.
- Published
- 2022